webinar register page

Webinar banner
Development of a genome-wide CRISPR screen in CD4+ T cells to identify drug targets for immune-mediated inflammatory diseases
Immune-mediated inflammatory diseases (IMIDs) are a group of disorders characterised by tissue inflammation as a result of dysregulated immune responses. This webinar will showcase the development of a genome-wide CRISPR screen in primary T cells to identify drug targets for IMIDs, and will cover key areas of workflow optimisation, including lentiviral transduction, Cas9 electroporation in bulk cell populations and fluorescence-activated cell sorting. Preliminary data obtained from a recent ‘mini screen’ will be discussed and the session will close with some key learnings from the workflow development process.

Apr 7, 2021 09:30 AM in Eastern Time (US and Canada)

* Required information

By registering, I agree to the Privacy Statement and Terms of Service.



Ricky Trigg
Senior Scientist @GlaxoSmithKline Pharma
Dr. Trigg obtained his PhD in cancer genomics from the University of Leicester and completed his postdoctoral work at the University of Cambridge. His postdoctoral work focused on identification of mechanisms of resistance to anti-cancer compounds in paediatric malignancies. In this project, he employed genome-wide CRISPR knockout and activation screens to identify novel drug targets and devised novel combination treatment strategies to prevent emergence of drug resistance in mouse cancer models. Dr. Trigg is a Senior Scientist in the Department of Functional Genomics at GSK and is responsible for conducting genome-wide CRISPR knockout screens in primary immune cells for target identification.